In 1984, all non-immune children under the age of 5 years in the Gambi
an villages of Keneba and Manduar were vaccinated against hepatitis B
virus (HBV). All children born in these villages since 1984 have been
vaccinated in infancy. Despite a rapid fall in antibody concentrations
, vaccine efficacy against HBV infection and chronic carriage of HBsAg
has increased with time. Overall, vaccine efficacies in 1993 against
HBV infection and chronic HBsAg carriage were 94.7% (95% CI 93.0-96.0)
and 95.3% (91.0-97.5), respectively. Breakthrough infections in vacci
nated children largely originate from chronic HBsAg carriers. Thus, we
tested 261 chronic carriers for HBV DNA and e antigen. The prevalence
of these markers of infectivity, and the amount of HBV DNA, decreased
greatly with age. Detailed studies of breakthrough infections over tw
o 4-year periods revealed that in the second period there were fewer t
han half the expected numbers of infections. Our findings suggest that
in Keneba acid Manduar longterm vaccination is progressively decreasi
ng HBV transmission by chronic carriers, since their infectivity dimin
ishes with time.